Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

A University of Manitoba-led study has successfully eliminated breast-cancer-derived brain tumors in mice, using a drug to ...

Brain metastases become more prevalent with each line of therapy in metastatic breast cancer and are more common in patients with certain cancer subtypes, new research shows.

Using a novel method that gives a readout of which proteins are in specific locations within cells, UT Southwestern Medical ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

Breast cancer is the most common cancer in women and the second leading cause of cancer-related deaths after lung cancer.

Therapies that unleash the immune system to fight tumors have greatly extended the lives of people with many types of cancer.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

A new ray of hope emerges from Russia with the development of a cancer vaccine that promises to eliminate tumors and metastasis.

Michigan State University researchers developed light-sensitive chemicals to treat breast cancer, proving effective in mice ...